Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses the treatment strategies for patients who develop secondary acute myeloid leukemia (AML) following hypomethylating agent (HMA) therapy. The video emphasizes that for patients who are fit and healthy enough, intensive induction therapy followed by allogeneic stem cell transplantation is considered the optimal approach. Additionally, Dr Wang explores the role of novel agents and combination therapies in managing secondary AML, highlighting the importance of personalized treatment plans based on individual patient profiles.